Oct 7, 2019

Medtronic Initiates Worldwide Pivotal Study of a New Approach to Treating Dangerously Fast Heart Rhythms

Study to Evaluate Novel Implantable Defibrillator System with a Lead Placed Outside the Heart and Veins

DUBLIN, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter...

DUBLIN, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

The first study implant procedures were performed recently by Ian Crozier, M.D., at Christchurch Hospital in Christchurch, New Zealand, and John Scherschel, M.D., at Prairie Heart Institute at HSHS St. John’s Hospital in Springfield, Ill. The principal investigator for the study is Paul Friedman, M.D., chair of the Midwest Department of Cardiovascular Medicine at Mayo Clinic, Rochester, Minn. Worldwide, the EV ICD system is investigational and not approved for sale or distribution.

“Along with the other study investigators, I am enthusiastic to evaluate the safety and efficacy of this new approach, and its potential to deliver lifesaving ICD therapy without the risks associated with leads inside the veins and heart, and without compromising on the features available in traditional ICDs,” said Bradley P. Knight, M.D., medical director of the Center for Heart Rhythm Disorders at Northwestern Medicine’s Bluhm Cardiovascular Institute at Northwestern Memorial Hospital.

The EV ICD pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that will assess the Medtronic EV ICD system in up to 400 patients at up to 60 sites in North America, Europe, the Middle East, Asia, Australia and New Zealand.

The study’s primary effectiveness endpoint is defibrillation testing success rate at implant. The primary safety objective is freedom from major system and/or procedural complications at six months after implant. Patients will be assessed at two weeks, three months, six months, and every six months thereafter.

“With the EV ICD system, we aspire to deliver a new standard in ICD therapy for patients who are at significant risk of life-threatening rhythms in the lower chambers of the heart,” said Rob Kowal, M.D., Ph.D., chief medical officer, vice president of medical affairs in the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic. “Our engineers have spent years developing this innovative system, and we appreciate the high level of interest and collaboration among our expert investigators and regulatory authorities worldwide to carry out the EV ICD pivotal study.”

The Medtronic EV ICD system is intended to provide the benefits of traditional, transvenous ICDs in a single system and implant procedure:

  •  Lifesaving defibrillation therapy;
  •  Anti-tachycardia pacing to terminate arrhythmias; 
  •  Post-shock pacing; and 
  •  Temporary, back-up, bradycardia pacing to address abnormally slow heart rates. 

It is the same size (33 cc) and shape, and is expected to have similar longevity as traditional ICDs. The EV ICD device is implanted below the left armpit (in the left mid-axillary region), and the lead is placed under the sternum (breastbone). New procedure tools guide the delivery of the system.

The EV ICD pivotal study follows the successful first-in-human chronic EV ICD pilot study, which evaluated 21 patients in New Zealand and Australia and was presented as a late breaking clinical trial at Heart Rhythm 2019, as well as early research and acute feasibility studies, including the ASD1 (Acute Sensing and Defibrillation), SPACE2 (Substernal Pacing Acute Clinical Evaluation), and ASD23 studies.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


1 Chan JYS, Lelakowski J, Murgatroyd FD et al. Novel Extravascular Defibrillation Configuration With a Coil in the Substernal Space: The ASD Clinical Study. J Am Coll Cardiol EP 2017;3:905-10. https://doi.org/10.1016/j.jacep.2016.12.026
2 Sholevar DP, Tung S, Kuriachan V, et al. Feasibility of extravascular pacing with a novel substernal electrode configuration: The Substernal Pacing Acute Clinical Evaluation Study. Heart Rhythm. 2018;15:536–542.DOI:http://dx.doi.org/10.1016/j.hrthm.2017.11.030
3 Boersma LVA, Merkely N, Neuzil P, et al. Therapy From a Novel Substernal Lead: The ASD2 Study. JACC: Clin Electrophysiol 2019; 5:186-196. DOI: https://doi.org/10.1016/j.jacep.2018.11.003


Tracy McNulty
Public Relations

Ryan Weispfenning
Investor Relations